“The drug price systems to restrict drug prices are obstacles forthe patient accessibility and pharmaceutical development”

Argumentswere suggested that the Insurance Benefit Policy weakenspatient accessibilityto drugs and also leads negative influences on development of the Korean pharmaceutical industry.

In order to improve this, the industry claimed that evaluation methods forinsurancebenefits need to be altered, and the Risk Allocation System and the Drug Price Management System also need to be revised.

More s...